FDA issues first-ever approval for liquid biopsy companion diagnostic
Michael Schubert |
Lung cancer is the leading cause of cancer deaths among both men and women, and with non-small cell lung cancer (NSCLC) being the most common type, it’s no surprise that plenty of attention is focused on finding ways to treat it. In particular, tailoring treatment and diagnosis has been a key aim of most researchers active in the field and one major step forward in this regard has been in the development of the drug erlotinib, which inhibits the epidermal growth factor receptor (EGFR) and has proven to be maximally effective in NSCLC patients with EGFR gene mutations. As with many mutation-targeting therapeutics, the hunt for an effective accompanying diagnostic has been ongoing, and one such test has proven itself worthy of a Food and Drug Administration (FDA) seal of approval – the first diagnostic of its kind to get the nod from the US regulators.
Read the full article now
Log in or register to read this article in full and gain access to The Pathologist’s entire content archive. It’s FREE!
Or register now - it’s free!
You will benefit from:
- Unlimited access to ALL articles
- News, interviews & opinions from leading industry experts
- Receive print (and PDF) copies of The Pathologist magazine